AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
Go back to AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma| AbbVie (NYSE: ABBV) | Delayed: 256.46 -3.75 (1.44%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $260.21 | 52 Week High | $68.12 | |||
| Open | $257.96 | 52 Week Low | $50.71 | |||
| Day High | $258.91 | P/E | 55.63 | |||
| Day Low | $255.58 | EPS | $4.61 | |||
| Volume | 4,729,804 | |||||
